Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.77 |
| ▸ | CA4 | P22748 | 1/20 | 0.77 |
| ▸ | CES1 | P23141 | 7/20 | 0.54 |
| ▸ | CES2 | O00748 | 6/20 | 0.54 |
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL27433238 | 0.96 | CA2 (0.71) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL11904021 | 0.89 | CA2 (0.74) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL28868137 | 0.89 | CA2 (0.74) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL28213043 | 0.88 | CA2 (0.81) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL28286831 | 0.88 | CA2 (0.81) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL27345977 | 0.88 | CA2 (0.90) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL431405 | 0.88 | CA2 (1.00) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL29175054 | 0.88 | CA2 (1.00) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL16115635 | 0.88 | CA2 (1.00) | CA2CA4CES1CES2CA1 | |
| Benzoic Acid SCHEMBL6123440 | 0.88 | CA2 (1.00) | CA2CA4CES1CES2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106065322-A | A multiple effect of automobile non freezing solution | 西安昕罗新能源科技有限公司 | 2016-11-02 | — | — | CN | claimed |
| WO-2024203528-A1 | HAIR CLEANSING AGENT COMPOSITION | 株式会社マンダム | 2024-10-03 | — | — | WO | disclosed |
| US-20230023289-A1 | ANTHRANILAMIDE COMPOSITION | FMC IP TECHNOLOGY GMBH (CH) | 2023-01-26 | — | — | US | disclosed |
| CN-109528699-B | Application of phentermine in preparing neuroprotective drugs | 石家庄以岭药业股份有限公司 | 2022-02-15 | — | — | CN | disclosed |
| WO-2021062338-A1 | ANTHRANILAMIDE COMPOSITION | FMC CORPORATION (US) | 2021-04-01 | — | — | WO | disclosed |
| CN-105147658-B | A kind of ferrous fumarate docusate sodium capsule | 哈尔滨瀚钧药业有限公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-104940165-B | A kind of capsule containing docusate sodium and danthron and preparation method thereof | 哈尔滨瀚钧药业有限公司 | 2018-01-16 | — | — | CN | disclosed |
| US-9744137-B2 | Topiramate compositions and methods of enhancing its bioavailability | SUPERNUS PHARMACEUTICALS, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| CN-106063808-A | The invention claims a traditional chinese medicine ointment | 贵州积黔网络有限公司 | 2016-11-02 | — | — | CN | disclosed |
| CN-106065322-A | A multiple effect of automobile non freezing solution | 西安昕罗新能源科技有限公司 | 2016-11-02 | — | — | CN | disclosed |
| EP-1954282-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | disclosed |
| US-20080085306-A1 | A delayed-release oral topiramate pharmaceutical composition, comprising a core of topiramate and an enteric coating around the core; once-daily or alternate day dosage; single dosage equivalent to the immediate-release multiple dose daily regimen; steady state blood levels; improved pharmacokinetics | SPHERICS, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| EP-1901721-A1 | DELAYED RELEASE OR EXTENDED-DELAYED RELEASE DOSAGE FORMS OF PRAMIPEXOLE | Spherics, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008027557-A2 | TOPIRAMATE COMPOSITIONS AND METHODS OF ENHANCING ITS BIOAVAILABILITY | SPHERICS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
| CN-100350903-C | Medicaments for treating colics | BENNETTS THE CHEMISTS PROPRIET (ZA) | 2007-11-28 | — | — | CN | disclosed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007002518-A1 | DELAYED RELEASE OR EXTENDED-DELAYED RELEASE DOSAGE FORMS OF PRAMIPEXOLE | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20050226926-A1 | Sustained-release tablet composition of pramipexole | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
| US-20050020589-A1 | Sustained-release tablet composition comprising a dopamine receptor agonist | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| CN-1449281-A | Medicaments for treating colics | BENNETTS THE CHEMISTS PROPRIET (ZA) | 2003-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020589-A1 | Sustained-release tablet composition comprising a dopamine receptor agonist | HRH2, HRH3, CNR1 | CA2 1287/4885CA4 2540/4885CES1 2725/4885 |
| US-20050226926-A1 | Sustained-release tablet composition of pramipexole | PKM, CRH, LPXN | CA2 771/4885CA4 1211/4885CES1 2769/4885 |
| US-20230023289-A1 | ANTHRANILAMIDE COMPOSITION | ACMSD, FADS2, AADAC | CA2 164/4885CA4 444/4885CES1 1325/4885 |
| US-20080085306-A1 | A delayed-release oral topiramate pharmaceutical composition, comprising a core of topiramate and an enteric coating around the core; once-daily or alternate day dosage; single dosage equivalent to the immediate-release multiple dose daily regimen; steady state blood levels; improved pharmacokinetics | SI, CYP3A5, CYP3A43 | CA2 1234/4885CA4 1566/4885CES1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.